Summary & Overview
HCPCS J3520: Edetate Disodium, 150 mg Intravenous Infusion
HCPCS Level II code J3520 designates edetate disodium in 150 mg units, an injectable chelating agent used in clinical settings that require intravenous administration. Nationally, this code matters for billing and coverage of infusion-based chelation therapies in hospital outpatient departments and standalone infusion centers. Accurate coding affects claims processing, payer coverage determinations, and clinical documentation for therapies that require monitored intravenous delivery.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for edetate disodium administration, common sites of service, and what to expect in payer coverage approaches. The publication summarizes benchmarks where available, highlights relevant policy and coverage considerations at a national level, and outlines coding implications for service line planning.
This resource is intended to clarify the role of J3520 in billing workflows, inform revenue cycle and clinical teams about common administrative contexts for edetate disodium infusion, and provide a concise reference on the code’s clinical and billing significance. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J3520 represents Edetate disodium, per 150 mg, an injectable chelating agent formulation. The service type is infusion/administration of a chelating agent, typically delivered as an intravenous infusion. The typical site of service is hospital outpatient departments or infusion centers, where intravenous drug administration and monitoring occur.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J3520 (edetate disodium, per 150 mg) is an adult undergoing chelation therapy for documented lead poisoning or for removal of heavy metals as indicated by toxicology results. The clinical workflow begins with evaluation in an occupational medicine, toxicology, or emergency department setting where elevated blood lead level (BLL) or other heavy metal concentrations are confirmed by laboratory testing. A treating physician (often a medical toxicologist, occupational medicine specialist, or emergency physician) documents the indication, baseline vital signs, renal function, and allergy status. Intravenous access is established and the calculated dose of edetate disodium is prepared by pharmacy, billed per 150 mg unit using J3520. The medication is administered intravenously under monitoring for hypersensitivity, hemodynamic stability, and renal parameters. Subsequent BLLs and clinical assessments guide additional doses and treatment duration. Typical sites of service include hospital inpatient units, emergency departments, infusion centers, and outpatient occupational medicine clinics where monitored IV chelation infusions are performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no special modifier applies to the service |